Case 1:
A 7-year-old male patient with high-risk AML developed initial gastrointestinal and ocular GVHD 23 days post-allogenic HSCT. He was initially on prednisone and sirolimus; first attempts included weaning him from prednisone with extracorporeal photopheresis (ECP), but he continued to have multiple skin GVHD flares with worsening manifestations to grade 4 aGVHD. Bortezomib was initiated due to continued steroid dependence (Table 1). Due to development of pancytopenia, dose reduction was required temporally, before increasing again. His skin lesions steadily improved, permitting bortezomib dose taper to discontinuation and discontinuation of prednisone with subsequently stopped all immune suppression.